Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,577.90 +0.43%
EUR-USD 1.2569 0.1086%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 91.22 +0.40%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: SIX Swiss Ex
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Santhera Pharmaceutical Holding AG

Add to Portfolio

SANN:SW

4.01 CHF 0.28 6.53%

As of 11:31:34 ET on 05/25/2012.

Snapshot for Santhera Pharmaceutical Holding AG (SANN)

Open: 4.26 Day's Range: 3.93 - 4.35 Volume: 5,336 Bid: 4.01
Previous Close: 4.29 52wk Range: 3.74 - 9.15 1-Yr Rtn: -52.82% Ask: 4.05

Stock Chart for SANN

No chart data available.
  • SANN:SW 4.01
  • 1D
  • 1M
  • 1Y
4.29
Interactive SANN Chart

Previous Close

Key Statistics for SANN

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (CHF) (ttm) -7.6000
Est. EPS (CHF) (12/2012) -7.7400
Est. PEG Ratio -
Market Cap (M CHF) 14.73
Shares Outstanding (M) 3.67
Enterprise Value (M CHF) (ttm) -
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 0.3420
Price/Sale (ttm) 4.5015
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/31/2012
More SANN Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for SANN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)
More SANN Income Statement Data
  • Total Assets
  • Total Liabilities (M/CHF)
  • Debt to Assets (%)
More SANN Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/CHF)
More SANN Cash Flow Data

Company Profile & Key Executives for SANN

Santhera Pharmaceuticals is a drug discovery and development company. The Company focuses on the discovery, preclinical and clinical development, and commercialization of pharmaceuticals for neuromuscular and metabolic diseases.

Michael E LyttonChairmanHans Peter HaslerVice Chairman
Klaus SchollmeierChief Executive OfficerHelmut KessmannChief Business Officer
More Company Profile & Key Executives for SANN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements